Ability of bifidobacteria to metabolize chitin-glucan and its impact on the gut microbiota by Alessandri, Giulia et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title Ability of bifidobacteria to metabolize chitin-glucan and its impact on
the gut microbiota
Author(s) Alessandri, Giulia; Milani, Christian; Duranti, Sabrina; Mancabelli,
Leonardo; Ranjanoro, Thibaut; Modica, Salvatore; Carnevali, Luca;
Statello, Rosario; Bottacini, Francesca; Turroni, Francesca; Ossiprandi,
Maria Cristina; Sgoifo, Andrea; van Sinderen, Douwe; Ventura, Marco
Publication date 2019-04-08
Original citation Alessandri, G., Milani, C., Duranti, S., Mancabelli, L., Ranjanoro, T.,
Modica, S., Carnevali, L., Statello, R., Bottacini, F., Turroni, F. and
Ossiprandi, M.C., 2019. Ability of bifidobacteria to metabolize chitin-
glucan and its impact on the gut microbiota. Scientific reports, 9(1),
(5755). DOI:10.1038/s41598-019-42257-z
Type of publication Article (peer-reviewed)
Link to publisher's
version
https://www.nature.com/articles/s41598-019-42257-z
http://dx.doi.org/10.1038/s41598-019-42257-z
Access to the full text of the published version may require a
subscription.
Rights © The Author(s) 2019
https://creativecommons.org/licenses/by/4.0/
Item downloaded
from
http://hdl.handle.net/10468/9085
Downloaded on 2020-06-06T00:52:26Z
1Scientific RepoRts |          (2019) 9:5755  | https://doi.org/10.1038/s41598-019-42257-z
www.nature.com/scientificreports
Ability of bifidobacteria to 
metabolize chitin-glucan and its 
impact on the gut microbiota
Giulia Alessandri1, Christian Milani  2, Sabrina Duranti2, Leonardo Mancabelli2, 
Thibaut Ranjanoro3, Salvatore Modica3, Luca Carnevali4, Rosario statello4, 
Francesca Bottacini  5, Francesca turroni2, Maria Cristina ossiprandi  1, Andrea sgoifo4, 
Douwe van sinderen5 & Marco Ventura1
Chitin-glucan (CG) represents a natural carbohydrate source for certain microbial inhabitants of the 
human gut and may act as a prebiotic for a number of bacterial taxa. However, the bifidogenic activity 
of this substrate is still unknown. In the current study, we evaluated the ability of chitin-glucan to 
influence growth of 100 bifidobacterial strains belonging to those species commonly identified within 
the bifidobacterial communities residing in the infant and adult human gut. Such analyses were coupled 
with transcriptome experiments directed to explore the transcriptional effects of CG on Bifidobacterium 
breve 2L, which was shown to elicit the highest growth performance on this natural polysaccharide. 
In addition, an in vivo trial involving a rat model revealed how the colonization efficiency of this 
bifidobacterial strain was enhanced when the animals were fed with a diet containing CG. Altogether 
our analyses indicate that CG is a valuable novel prebiotic compound that may be added to the human 
diet in order to re-establish/reinforce bifidobacteria colonization in the mammalian gut.
Chitin-glucan (CG) is a high-purity bio-polymer composed of two distinct polysaccharides represented by chitin 
(β-1,4-poly-N-acetyl-D-glucosamine) and β-1,3-D-glucan in a ratio ranging from 20:80 to 40:60 (w/w)1. CG is 
typically extracted from Aspergillus niger mycelial cell walls. Furthermore, another natural sources of CG are rep-
resented by different fungal species and yeasts due to the presence of this bio-polymer in their inner cell walls2,3. 
Recently, CG has been indicated as food supplements fixing the maximum consumption rate to five gr per day 
for an average person4.
However, mammalian enzymes are unable to degrade CG and therefore following ingestion this glycopoly-
mer will arrive in its intact form in the large intestine where it may influence growth and/or metabolic activity of 
different members of the gut microbiota. In this context, there is growing scientific evidence of possible prebiotic 
effects elicited by CG towards various microorganisms of the mammalian gut5,6. Recently, an in vitro study per-
formed in a dynamic gut simulator (SHIME) illustrated the effect of CG on microbiota composition and activity, 
leading to a decrease of the Firmicutes/Bacteroidetes ratio and an increase in the relative abundance of Roseburia 
spp1, which could suggest a potential role exploited by CG in shaping the gut microbiota through a prebiotic effect 
as previously displayed for other complex carbohydrates7.
The term ‘prebiotic’ includes compounds, such as non-digestible (i.e. cannot be metabolized or degraded by 
the host) carbohydrates, that are selectively metabolized by beneficial gut bacteria. Prebiotic treatment is a dietary 
strategy by which the gastrointestinal microbiota can be modified, both in composition and/or activity, for the 
purpose of conferring health benefits to the host8. In fact, it has been demonstrated that prebiotics can reduce 
symptoms associated with inflammatory bowel disease, the duration of infectious and antibiotic-associated diar-
rhea, and the risk of cardiovascular diseases. Furthermore, prebiotics may also promote satiety and weight loss, 
preventing obesity and enhancing protective effects against the onset of colon cancer9.
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Bifidobacteria are very prevalent and abundant human gut microbiota members, especially during the first 
months following birth10, though their numbers decrease following weaning and in elderly. Bifidobacterial abun-
dance in the human microbiota is markedly reduced following gastrointestinal diseases11, suggesting that this 
taxon plays a positive role in the promotion of host health12. Prebiotics, such as dietary fibers, have been used to 
counteract the reduction of bifidobacterial abundance in the human gut13.
So far, a very limited scientific evidence is available regarding the possible prebiotic effect of CG towards 
members of the Bifidobacterium genus6. In the current report, we evaluated possible bifidogenic features of CG 
towards 100 different bifidobacterial strains using an in vitro approach. Such analyses revealed the presence of a 
highly CG-responsive bifidobacterial strain, Bifidobacterium breve 2L, whose transcriptome when cultivated on 
CG was investigated in detail by RNAseq experiments. Furthermore, in vivo trials in a rat model fed with CG and 
B. breve 2L clearly demonstrated that CG increases the abundance of B. breve 2L and several other members of 
the mammalian gut microbiota.
Results and Discussion
Evaluation of prebiotic capability of chitin-glucan toward bifidobacteria. One hundred bifido-
bacterial strains previously isolated from the human environment (reported in Table 1), were evaluated for their 
ability to grow on CG, as unique carbon source. These strains were isolated from infant feces (Bifidobacterium 
bifidum, Bifidobacterium breve and Bifidobacterium pseudocatenulatum) as well as from gastrointestinal tract of 
adult (Bifidobacterium adolescentis, Bifidobacterium angulatum, Bifidobacterium catenulatum, Bifidobacterium 
dentium, Bifidobacterium longum, Bifidobacterium pseudolongum subsp. globosum). In addition, the bifidobac-
terial collection used in this project included strains belonging to Bifidobacterium animalis subsp. lactis, isolated 
from various commercial products sold as probiotics. Despite the fact that CG consists of two different poly-
saccharides, i.e. chitin (β-1,4-poly-N-acetyl-D-glucosamine) and β-1,3-D-glucan, we focused our study on the 
biopolymer CG due to its commercial relevance as an extract of Aspergillus niger. Furthermore, we have used 
the Tyndallization procedure, which operates a series moderate heat treatment steps separated by rapid cooling 
stages, in order to achieve a sterilization of CG-based medium without causing extensive hydrolysis of CG as 
might occur when using high-level temperature treatments such as autoclaving. Growth assays were conducted 
on a modified MRS growth media, i.e. MRS w/o glu + CG (0.5% (w/v) together with a positive control (complete 
MRS) as well as a negative control (MRS w/o glu). Experiments were performed in triplicates for each growth 
media. We observed a minimal growth also on MRS w/o glu (≤103 cells/ml), which is probably linked to the 
presence of components such as meat and yeast extract providing extra organic carbon sources. However, the 
final cell count of positive control and MRS w/o glu + CG were calculated by subtracting the cells count obtained 
on MRS w/o glu. Interestingly, all strains were shown to exhibit growth using MRS w/o glu + CG as the unique 
carbon source. Remarkably, almost all assayed strains displayed growth levels comparable with those obtained in 
complete MRS (MRS + glucose), i.e. comprised between 107–109 cells/mL (Table 1). Notably, this may be caused 
by partial degradation of CG in simpler sugars, e.g. glucose monomers from glucan, due to the heat treatment 
included in the modified Tyndallization approach employed to sterilize the MRS w/o glu + CG medium. Only in 
case of strains belonging to the B. adolescentis and B. longum species, the observed growth levels were significantly 
different (p-value < 0.05) (Fig. 1). In detail, B. adolescentis strains exhibited a final cell count of 7.59 × 107 cells/
mL, and 4.19 × 108 cells/mL, in MRS w/o glu + CG and in complete MRS, respectively. Regarding B. longum, 
these strains were able to reach an average final cell count of 4.40 × 108 cells/mL in MRS w/o glu + CG, which is 
a lower cell yield compared to the final cell count in complete MRS (1.05 × 109 cells/mL). This finding indicates 
that these bifidobacterial species have a reduced ability to utilize CG as compared to the other assessed bifido-
bacterial strains. In contrast, B. breve and B. bifidum strains were shown to reach the highest cell numbers on this 
substrate (cell numbers ranging from 108 to 109 cells/mL), and in some cases surpassing growth yields obtained in 
complete MRS (Fig. 1). These two bacterial species are typically isolated from infants, and consequently expected 
to be metabolically adapted to degrade host-specific glycans such as mucin and host glycan constituents like 
N-acetylglucosamine14,15. Notably, CG is partially composed of polymerized β-1,4-poly-N-acetyl-D-glucosamine, 
which may explain the reason for the more robust metabolic efficiency of these species toward CG (compared to 
the other examined bifidobacterial species).
For those bifidobacterial strains showing an identical or higher growth level in MRS w/o glu + CG vs. MRS, 
growth performances were further evaluated using a different approach, i.e. viable cell count on MRS Agar 
(Table 1). Moreover, three bifidobacterial strains, i.e., B. bifidum LMG 11041, B. breve 31L and B. dentium LMG 
11405, were selected as controls, since these strains showed reduced growth levels in MRS w/o glu + CG when 
compared to the cell numbers reached when grown on MRS.
Interestingly, all counts obtained through the plating method were lower than those obtained employing the 
Thoma cell counting chamber. This may not be surprising, since the Thoma chamber utilizes an indirect count-
ing method and is unable to distinguish between living or devitalized cells, while the plating method exclusively 
evaluates viable cells. Notably, all strains grown using CG as the sole carbon source and then plated on MRS Agar 
were shown to be able to utilize the substrate tested. Bacterial counts ranged from 2.09 × 104 CFU/mL for B. breve 
31L cultures to 1.33 × 108 CFU/mL for B. breve 2L cultures. Thus, B. breve 2L was the strain showing the highest 
growth performance when CG was provided as the sole carbon source. For this reason, B. breve 2L was chosen as 
a model bifidobacterial strain to dissect the genetic repertoire responsible for efficient CG metabolism.
Identification of genes induced by CG in the genome of B. breve 2L. In order to identify the genes 
of B. breve 2L responsible for CG metabolism, we evaluated the transcriptomes of this strain when cultivated on 
CG by RNAseq analyses. The average transcriptome profile corresponding to the three replicates of B. breve 2L 
cultivated on MRS w/o glu + CG (0.5%(w/v) as the unique carbon source was compared with the average tran-
scriptome profile of the three replicates of the positive control (B. breve 2L grown on complete MRS). Sequencing 
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Strainsa Origin
Average 
(cells/mL) SD
Average CG 
(cells/mL) CG SD
Average Agar 
plate (CFU/mL)
Agar 
plate SD
B. adolescentis 1901B Adult stool sample 1.03 × 108 4.63 × 107 3.42 × 107 2.67 × 107
B. adolescentis 1902B Adult stool sample 6.17 × 108 2.08 × 108 2.92 × 107 8.04 × 106
B. adolescentis 1903B Adult stool sample 2.75 × 108 1.52 × 108 4.75 × 107 2.88 × 107
B. adolescentis 1904B Adult stool sample 2.50 × 108 2.38 × 108 3.33 × 108 3.64 × 108 8.40 × 106 2.06 × 106
B. adolescentis 22L Human milk 3.67 × 108 1.94 × 108 2.83 × 107 1.18 × 107
B. adolescentis 236B Colonoscopic sample 2.17 × 108 1.59 × 108 4.00 × 107 4.33 × 106
B. adolescentis 382B Adult stool sample 5.08 × 108 3.13 × 108 7.17 × 107 9.46 × 106
B. adolescentis 388B Adult stool sample 1.17 × 108 5.20 × 107 2.26 × 108 1.13 × 108 3.75 × 107 8.57 × 106
B. adolescentis 42B Adult stool sample 2.75 × 108 8.66 × 107 1.83 × 107 1.04 × 107
B. adolescentis 487B Adult stool sample 4.08 × 108 1.89 × 108 3.83 × 107 1.89 × 107
B. adolescentis 532B Colonoscopic sample 3.83 × 108 1.23 × 108 1.02 × 108 2.25 × 107
B. adolescentis 548B Colonoscopic sample 2.67 × 108 3.82 × 107 6.00 × 107 1.73 × 107
B. adolescentis 59B Adult stool sample 3.08 × 108 8.04 × 107 2.50 × 107 4.33 × 106
B. adolescentis 61B Adult stool sample 1.58 × 108 1.44 × 107 2.25 × 107 1.98 × 107
B. adolescentis 65B Colonoscopic sample 5.75 × 108 1.95 × 108 4.50 × 107 1.09 × 107
B. adolescentis 679B Adult stool sample 1.75 × 108 5.00 × 107 6.00 × 107 6.61 × 106
B. adolescentis 703B Adult stool sample 9.75 × 108 5.91 × 108 5.82 × 107 4.04 × 107
B. adolescentis 70B Adult stool sample 4.33 × 108 1.76 × 108 2.25 × 107 1.41 × 107
B. adolescentis 711B Colonoscopic sample 8.67 × 108 5.20 × 107 1.75 × 108 1.00 × 108
B. adolescentis 723B Colonoscopic sample 1.57 × 109 4.15 × 108 8.42 × 107 7.88 × 107
B. adolescentis 731B Colonoscopic sample 7.42 × 108 1.38 × 108 9.92 × 107 5.43 × 107
B. adolescentis 734B Colonoscopic sample 3.17 × 107 1.44 × 107 1.13 × 107 5.30 × 106
B. adolescentis ATCC 15703 Colonoscopic sample 7.33 × 107 2.50 × 107 2.17 × 107 5.20 × 106
B. adolescentis LMG 10733 Colonoscopic sample 1.09 × 109 3.17 × 108 5.33 × 107 3.82 × 106
B. adolescentis LMG 10734 Colonoscopic sample 1.27 × 108 3.16 × 107 6.00 × 107 0
B. adolescentis LMG 18897 Adult stool sample 5.83 × 108 1.81 × 108 2.50 × 107 7.07 × 106
B. angulatum LMG 11039 Adult stool sample 1.25 × 108 6.61 × 107 3.50 × 108 3.68 × 108
B. animalis subsp. lactis Bb-12 Fermented milk product 7.17 × 108 4.25 × 108 1.45 × 109 2.78 × 108 8.30 × 106 2.43 × 106
B. animalis subsp. lactis DSM 10140 Fermented milk 2.50 × 108 4.33 × 107 1.08 × 108 5.20 × 107
B. bifidum 156B Infant stool sample 2.58 × 108 1.66 × 108 6.42 × 108 8.78 × 107 2.61 × 106 2.75 × 105
B. bifidum 324B Infant stool sample 1.67 × 108 1.04 × 108 1.83 × 108 5.20 × 107 2.58 × 106 4.15 × 105
B. bifidum 361B Adult stool sample 5.00 × 107 2.50 × 107 4.00 × 107 1.15 × 107
B. bifidum 85B Infant stool sample 3.25 × 108 1.25 × 108 3.17 × 108 2.89 × 107
B. bifidum LMG 11041 Infant stool sample 1.83 × 108 1.44 × 108 4.92 × 107 1.44 × 106 8.14 × 106 9.27 × 105
B. bifidum LMG 11582 Adult stool sample 5.42 × 108 8.04 × 107 5.67 × 108 1.42 × 108 1.62 × 107 4.55 × 106
B. bifidum LMG 11583 Adult stool sample 2.08 × 108 7.64 × 107 1.23 × 109 3.44 × 108 5.00 × 106 5.35 × 105
B. bifidum LMG 13195 Infant colonoscopic sample 9.58 × 10
7 2.67 × 107 6.42 × 107 5.20 × 106
B. bifidum LMG 13200 Infant stool sample 7.08 × 108 3.83 × 108 1.04 × 109 1.01 × 108
B. bifidum PRL2010 Infant stool sample 5.42 × 108 2.40 × 108 1.13 × 109 1.95 × 108 4.15 × 107 4.74 × 106
B. breve 12L Human milk 1.30 × 109 1.26 × 109 1.43 × 109 1.32 × 108 7.43 × 107 6.56 × 106
B. breve 2L Human milk 1.23 × 109 5.13 × 108 1.42 × 109 7.52 × 108 1.33 × 108 2.74 × 107
B. breve 31L Human milk 1.17 × 109 5.77 × 108 3.25 × 108 6.61 × 107 2.09 × 104 1.10 × 104
B. breve 687B Adult stool sample 1.55 × 109 1.42 × 108 1.46 × 109 1.68 × 108
B. breve 689B Adult stool sample 1.73 × 109 1.95 × 108 2.68 × 108 7.39 × 107
B. breve 691B Adult stool sample 9.08 × 108 1.26 × 108 1.72 × 109 2.88 × 108 1.11 × 108 5.13 × 106
B. breve LMG 13208 Infant colonoscopic sample 2.33 × 10
8 1.44 × 107 3.35 × 108 9.84 × 107 4.34 × 107 8.40 × 106
B. catenulatum 1231B Human gut 1.00 × 108 5.00 × 107 6.00 × 107 5.00 × 106
B. catenulatum 1232B Human gut 1.67 × 108 8.04 × 107 1.09 × 108 1.91 × 107
B. catenulatum 1233B Human gut 2.67 × 108 1.42 × 108 1.13 × 108 3.03 × 107
B. catenulatum 1234B Human gut 2.08 × 108 1.46 × 108 8.00 × 107 2.70 × 107
B. catenulatum LMG 11043 Colonoscopic sample 8.48 × 108 1.49 × 108 2.17 × 108 1.18 × 108
B. dentium 125B Adult stool sample 1.53 × 109 4.04 × 108 2.25 × 108 1.25 × 108
B. dentium 181B Adult stool sample 3.83 × 108 1.53 × 108 7.33 × 107 2.84 × 107
B. dentium 183B Adult stool sample 3.00 × 108 1.75 × 108 6.08 × 107 1.66 × 107
B. dentium 369B Adult stool sample 6.42 × 108 2.45 × 108 1.08 × 108 2.60 × 107
Continued
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reads of B. breve 2L grown on CG as well as on glucose were mapped on the genome sequence of B. breve 2L. 
Subsequently, evaluation of RPKM (reads per kilobase per million mapped reads) values for each gene revealed 
high expression (ranging from 1464 to 24685 RPKM) of genes predicted to encode carbohydrate transporters 
(Table S1, annotation highlighted in red).
Notably, B. breve 2L grown in MRS w/o glu + CG (0.5% (w/v) showed increased transcription, ranging from 
8.1 to 106-fold, of various genes, some of which were predicted to be involved in carbohydrate internalization 
Strainsa Origin
Average 
(cells/mL) SD
Average CG 
(cells/mL) CG SD
Average Agar 
plate (CFU/mL)
Agar 
plate SD
B. dentium LMG 11405 Oral cavity 1.67 × 108 1.26 × 108 6.67 × 107 1.44 × 107 3.19 × 106 2.75 × 106
B. gallicum LMG 11596 Colonoscopic sample 5.92 × 108 2.31 × 108 7.67 × 108 2.93 × 108 5.72 × 107 7.25 × 106
B. longum 123B Colonoscopic sample 1.50 × 109 9.01 × 108 4.33 × 108 1.38E × 108
B. longum 134B Colonoscopic sample 1.33 × 108 7.64 × 107 1.75 × 108 7.50 × 107 1.85 × 107 6.03 × 106
B. longum 159B Colonoscopic sample 1.58 × 108 5.20 × 107 2.58 × 108 8.04 × 107 1.77 × 106 7.33 × 105
B. longum 207B Colonoscopic sample 1.67 × 107 1.42 × 107 6.67 × 107 2.27 × 107 1.86 × 107 3.96 × 106
B. longum 220B Colonoscopic sample 3.08 × 108 1.66 × 108 3.00 × 108 2.84 × 108
B. longum 224B Colonoscopic sample 2.00 × 109 4.33 × 108 1.57 × 109 2.25 × 108
B. longum 229B Colonoscopic sample 4.92 × 109 2.16 × 109 9.08 × 108 2.01 × 108
B. longum 296B Adult stool sample 1.42 × 109 1.18 × 109 6.00 × 108 1.75 × 108
B. longum 314B Colonoscopic sample 2.08 × 108 5.20 × 107 2.50 × 108 0 1.78 × 107 3.30 × 106
B. longum 319B Colonoscopic sample 3.50 × 108 3.04 × 108 5.25 × 108 1.89 × 108 3.53 × 107 1.74 × 107
B. longum 340B Adult stool sample 8.92 × 108 1.46 × 108 2.17 × 108 5.20 × 107
B. longum 346B Adult stool sample 3.33 × 108 2.13 × 108 3.25 × 108 1.50 × 108
B. longum 350B Adult stool sample 4.58 × 108 1.44 × 107 2.42 × 108 1.01 × 108
B. longum 351B Adult stool sample 1.42 × 108 7.64 × 107 7.17 × 107 3.82 × 106
B. longum 397B Adult stool sample 1.07 × 109 7.51 × 107 5.25 × 108 1.15 × 108
B. longum 419B Adult stool sample 5.00 × 108 1.32 × 108 4.25 × 108 1.52 × 108
B. longum 428B Adult stool sample 8.25 × 108 3.27 × 108 2.75 × 108 9.01 × 107
B. longum 432B Adult stool sample 1.39 × 109 2.69 × 108 5.08 × 108 2.27 × 108
B. longum 433B Adult stool sample 2.50 × 109 5.00 × 108 1.15 × 109 4.95 × 108
B. longum 434B Adult stool sample 1.92 × 109 1.26 × 109 5.50 × 108 7.50 × 107
B. longum 442B Adult stool sample 6.08 × 108 5.20 × 107 7.33 × 108 2.25 × 108 7.38 × 105 7.61 × 104
B. longum 447B Adult stool sample 1.13 × 109 4.06 × 108 2.83 × 108 1.46 × 108
B. longum 451B Adult stool sample 1.31 × 109 3.06 × 108 5.08 × 108 2.75 × 108
B. longum 499B Colonoscopic sample 3.00 × 108 1.15 × 108 5.17 × 107 3.82 × 106
B. longum 553B Colonoscopic sample 2.33 × 109 5.20 × 108 5.92 × 108 2.60 × 108
B. longum 606B Colonoscopic sample 9.17 × 107 9.46 × 107 2.50 × 106 0
B. longum 633B Adult stool sample 2.92 × 109 1.88 × 109 8.75 × 108 2.54 × 108
B. longum 707B Adult stool sample 9.25 × 108 7.15 × 108 3.75 × 108 1.56 × 108
B. longum 71B Adult stool sample 3.00 × 107 8.66 × 106 2.42 × 107 6.29 × 106
B. longum 743B Adult stool sample 1.58 × 108 1.46 × 108 4.92 × 107 2.63 × 107
B. longum 861B Adult stool sample 1.83 × 108 5.77 × 107 2.42 × 108 7.64 × 107 8.86 × 105 1.54 × 105
B. longum 908B Colonoscopic sample 2.07 × 109 4.16 × 108 8.75 × 108 6.61 × 107
B. longum subsp. longum LMG 13197 Colonoscopic sample 1.42 × 109 7.22 × 108 5.33 × 108 4.47 × 108
B. pseudocatenulatum 202B Colonoscopic sample 4.45 × 108 3.82 × 108 3.08 × 108 1.28 × 108
B. pseudocatenulatum 263B Adult stool sample 3.42 × 108 2.45 × 108 9.67 × 107 2.89 × 107
B. pseudocatenulatum 289B Adult stool sample 2.50 × 108 4.33 × 107 9.33 × 107 6.29 × 106
B. pseudocatenulatum 318B Colonoscopic sample 3.33 × 108 8.04 × 107 1.92 × 108 1.44 × 107
B. pseudocatenulatum LMG 10505 Infant stool sample 1.67 × 109 1.28 × 109 6.67 × 107 1.44 × 107
B. pseudolongum subsp. globosum 555B Colonoscopic sample 1.33 × 108 2.89 × 107 3.75 × 108 2.50 × 107 5.52 × 105 5.89 × 105
B. pseudolongum subsp. globosum 685B Adult stool sample 2.58 × 108 1.44 × 108 3.17 × 108 1.42 × 108 4.89 × 107 3.86 × 106
B. pseudolongum subsp. globosum 686B Colonoscopic sample 3.08 × 108 2.04 × 108 1.83 × 108 5.91 × 107
B. pseudolongum subsp. globosum 
LMG 11596 Bovine rumen 5.83 × 10
7 3.82 × 107 7.50 × 107 3.54 × 107 4.05 × 107 1.17 × 107
B. stercoris JCM 15918 Adult stool sample 7.92 × 107 2.13 × 107 1.25 × 107 2.50 × 106
Table 1. Bifidobacterial strains grown on MRS medium and MRS w/o glucose supplemented with CG and 
results of in vitro experiments. aATCC: American Type Culture Collection, USA; LMG, Belgian Co-ordinated 
Collection of Microorganisms-Bacterial Collection, Belgium; DSM, German Collection of Microorganism and 
Cell Cultures, Germany; JCM Japan Collection of Microorganisms, Japan. bEC: Enzyme Commission. Values 
are expressed as the means ± standard errors from three experiments.
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(Table S2, annotation highlighted in red). Furthermore, significant transcriptional up-regulation, ranging from 
8.2-fold to 14.6-fold, was observed for three genes encoding enzymes putatively involved in the hydrolysis of 
glycosidic linkages between hexose sugars (Table S2, annotation highlighted in blue).
A detailed scrutiny of the upregulated B. breve 2L genes upon its cultivation on MRS w/o glu + GC, revealed 
that the majority of these genes were organized in seven loci, which are predicted to encode carbohydrate trans-
port systems (Table S3, annotation highlighted in red), or are coding for putative glycosyl hydrolases (Table S3, 
annotation highlighted in blue).
Altogether, these results indicate that the inclusion of CG in the growth medium as the unique carbohydrate 
source, modulates the expression of genes encoding enzymes toward the degradation and metabolism of CG.
Notably, CG was also observed to increase transcription of tad genes (Table S3, annotation highlighted in 
green) responsible for the synthesis and assembly of the Type IVb pilus locus, which has been shown in another 
B. breve strain to mediate the colonization and persistence of bifidobacterial cells in the mammalian gut16–18.
Evaluation of the colonization of B. breve 2L in rats following GC treatment. In order to evaluate 
if CG is able to modulate colonization of B. breve 2L in the mammalian gut, we performed an in vivo trial using 
Groningen rats (Rattus norvegicus). The trial consisted of three groups of animals, one receiving a daily inocu-
lum of approximately 109 CFU of B. breve 2L, i.e., Breve2L, a second group fed with standard diet supplemented 
with 10% CG, i.e., CG, and another one treated with the same amount of B. breve 2L cells plus 10% CG, i.e., 
CG + Breve2L (Fig. 2).
The putative physiological effect of CG on the Body Weight (BW) of the animals was recorded and com-
pared to the Food Intake (FI) (Fig. 2b,c). Two-way ANOVA for repeated measures provided a significant effect 
of CG over time for BW changes (p-value < 0.05) and FI/BW (p-value < 0.01). BW increment was significantly 
higher in the Breve2L group as compared to the CG + Breve2L group at the end of the intervention period 
(T2) (p-value < 0.05). FI/BW ratio was significantly higher in the Breve2L group compared to either the CG 
(p-value < 0.05) or CG + Breve2L groups (p-value = 0.01), after the first week of the intervention period (T1). 
These data suggest that CG stimulates appetite while reducing/limiting body weight increment. In this context, 
characterization of the modulatory effects of CG toward the mammalian gut microbiota composition is pivotal to 
understand the physiological and metabolic aspects responsible for the reduction of body weight.
In order to assess the number of B. breve 2L in the fecal samples of the animals enrolled in this study, we 
applied a qPCR approach (Fig. 3). These analyses highlighted that rats of the CG groups did not show a statisti-
cally significant increment of B. breve 2L at the end of the experiment (T3) compared to the other time points. In 
contrast, a statistically significant increased load of B. breve 2L (p-value < 0.05) was observed at time points T1 
(1.14E + 03 CFU/gr) and T2 (1.20E + 03 CFU/gr) compared to T0 (3.30E + 02 CFU/gr) in the Breve2L group, 
but there were no significant differences with respect to T3 (9.58E + 02 CFU/gr). These data suggest that the daily 
administration of B. breve 2L allows a transient colonization of the bacterial species as its concentration decreases 
after the washout week (T3). In this context, when rats were fed with both CG and B. breve 2L, the abundance of 
the B. breve strain was higher in T2 (4.37E + 03) and T3 (2.85E + 03) as compared to that observed for rats fed 
with only B. breve 2L, i.e. 1.20E + 03 CFU/gr at T2 and 9.58E + 02 CFU/gr at T3. Thus, supplementation of CG in 
the standard diet appeared to cause an increase in the abundance of B. breve 2L, thus enhancing gut colonization/
persistence of this strain.
Characterization of CG effects on the rat gut microbiota composition. Evaluation of the gut 
microbiota composition of the animals enrolled in this study was performed by 16 S gene rRNA microbial profil-
ing analyses on fecal samples collected during the trial. Analysis of sequencing data produced a total of 4,581,503 
quality-filtered reads with an average of 47,724 reads per sample (Table S4). Evaluation of alpha-diversity, i.e. the 
biodiversity, of the collected rat fecal samples was performed through analysis of rarefaction curves constructed 
with 10 sub-sampling of the whole sequenced datasets. Notably, alpha-diversity data revealed, as expected, that at 
T0 all animal groups possessed similar microbiota diversity (t-test p-values > 0.05) (Fig. 3). T0 samples were used 
as “Control” non-treated group for analysis of T1, T2 and T3 time points. Intriguingly, analysis of data collected 
for T1 and T2 revealed that CG supplementation appeared to reduce the microbiota diversity, as observed for 
CG and CG + Breve2L compared to T0 and Breve2L sample groups (Fig. 4). These observations were confirmed 
by statistical analysis by means of t-test at 20,000 reads of CG and CG + Breve2L with respect to the same ani-
mal at T0, resulting in p-values < 0.05 (Fig. 4). Furthermore, data collected at T3 showed that cessation of CG 
supplementation does not reverse the biodiversity of the CG and CG + Breve2L groups to pre-treatment levels. 
These observations indicate that CG modulates the microbiota through selection of specific bacterial taxa, with 
subsequent reduction of the overall gut microbiota diversity, which persists (at least for the period tested) follow-
ing termination of CG supplementation. Similar data were previously observed for other prebiotic compounds7.
Beta-diversity analysis did not reveal any statistically significant differences between sample groups at T0 
(PERMANOVA p-value > 0.05) and confirmed the modulatory effect exerted by CG at T1 and T2 (Fig. 5). In 
fact, PERMANOVA statistical analysis between CG and CG + Breve2L groups at T1 and T2 with respect to T0 
datasets resulted in all cases in p-values < 0.05 (Fig. 5). Notably, cessation of CG supplementation causes the 
CG and CG + Breve2L sample groups to cluster together with Breve2L and Control datasets at T3 (Fig. 5). Thus, 
beta-diversity data confirms the modulatory effect exerted by CG on the animals’ gut microbiota composition.
Taxonomic composition of all samples was reconstructed at phylum and genus levels in order to detail the 
impact of CG on the gut microbiota (Supplementary File 1). A t-test between the relative abundance of each 
profiled bacterial genus observed in the CG, Breve2L and CG + Breve2L groups was performed and compared 
between the various time points. Furthermore, statistically significant taxa observed for each comparison were 
mapped in order to precisely identify those bacterial genera whose relative abundance was increased or decreased 
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upon CG and/or B. breve 2 L supplementation (Fig. 6). Intriguingly, 10 and 12 taxa showed increased (when com-
pared to T0) relative abundance during CG supplementation at T1 and T2, respectively, followed by a decrease in 
abundance at T3, i.e. after cessation of CG supplementation (Fig. 6). In this context, it is worth mentioning that 
Prevotella 1, U. m. of Prevotellaceae family and Eubacterium ventriosum group (Lachnospiraceae family) increased 
their abundance by 100%, 145.4% and 2072.5% in T2 when compared to T0 (Fig. 6) (Supplementary File 1). In 
contrast, 42 and 38 taxa showed decreased relative abundance at T1 and T2, respectively, followed by an increase 
in abundance at T3 (Fig. 6) (Supplementary File 1). The observed decreased relative abundance of Bacteroides 
as well as Ruminococcus (−15.5% and −67.2% in T2 when compared to T0) and the simultaneous increase in 
Figure 1. Bifidobacterial growth in MRS and chitin-glucan. The dispersion graphs report bacterial growth for 
the different bifidobacterial species included in this study, expressed as cells/mL. Panel a shows the growths in 
complete MRS (in red), while panel b depicts growths in MRS w/o glu + CG (in blue). Each growth reported is 
the average value of three experiments.
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relative abundance of Prevotella suggest that CG promotes a shift of the gut microbiota towards a Type 2 entero-
type, i.e. Prevotella-driven enterotype19.
Intriguingly, CG was observed to induce increased relative abundance of Akkermansia, a taxon with 
health-promoting activities20 and reduced relative abundance of Peptoclostridium, a genus encompassing oppor-
tunistic pathogens21.
Analysis of the impact of B. breve 2L and CG administration on the animal microbiota could not be accurately 
performed through 16S rRNA gene microbial profiling due to the low relative abundance of bifidobacteria in 
the assessed fecal samples. For this reason, we performed a detailed cataloguing of bifidobacterial communities 
through the use of a previously published bifidobacterial ITS profiling approach22,23, allowing a detailed catalogu-
ing of the bifidobacterial population down to the (sub)species level.
Cataloguing of the rat fecal bifidobacterial communities residing. In order to detail the impact of 
CG supplementation on the bifidobacterial population colonizing the rat gut, we performed bifidobacterial ITS 
Figure 2. Design and results of the experimental procedure. Panel a shows the schedule of the experimental 
procedures. Panel b and c display the body weight and food intake percentage changes relative to the respective 
‘T0’ values, during the experiment, respectively. Values are expressed as means ± SEM.
Figure 3. Quantitative PCR evaluations of the load of B. breve 2L in stool samples of rats. The graph reports the 
average abundance of B. breve 2L observed through qPCR in CG, Breve2L and CG + Breve2L groups at T0, T1, 
T2 and T3.
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profiling of DNA extracted from all fecal samples collected in this study. Sequencing produced a total of 316,080 
reads, with an average of 3,293 reads per sample (Table S5).
In order to detail the modulatory effects of CG, we performed inspection of (sub)species-level profiles and sta-
tistical analysis through t-test of CG, Breve2L as well as CG + Breve2L groups of samples at T1, T2 and T3 com-
pared to T0 (Supplementary File 2). As expected, an increase in the relative abundance of B. breve was observed 
in the Breve2L and CG + Breve2L groups at T1 and T2, which was followed by a relative decrease in B. breve 2L 
abundance at T3 (Fig. 7). Moreover, data of samples constituting the CG group revealed that CG supplementation 
induces a statistically significant increase in relative abundance (p-value < 0.05) of eight bifidobacterial species at T2 
(Supplementary File 2). Furthermore, when CG was supplemented in combination with B. breve 2L, this bifidobac-
terial species (and most likely the B. breve 2L strain) was shown to reach a higher relative abundance as compared to 
those animals only receiving B. breve 2L (Fig. 7), as also indicated by qPCR results (Fig. 2). These results indicate that 
CG exerts a species-specific modulation of the bifidobacterial population harbored by the rat gut.
Conclusion
Evaluation of the potential prebiotic features of chitin-glucan toward bifidobacteria under in vitro conditions 
highlighted the ability of 100 bifidobacterial strains to use this substrate as its sole carbon source. The bifidobac-
terial species that was most effective in utilizing CG for growth was shown to be B. breve. Notably, these results 
reflect the ability of this typical infant gut colonizer to utilize host-produced glycans, whose molecular structure 
partially resembles that of CG.
Figure 4. Alpha-diversity of CG, Breve2L and CG + Breve2L at T0, T1, T2 and T3 time points. Panels (a–d) 
report average alpha-diversity obtained using Chao1 index for T0, T1, T2 and T3 time points, respectively.
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RnaSeq transcriptomics data was performed for the B. breve strain showing the best CG utilization capabili-
ties, i.e. B. breve 2L, pointing out a modulation of the B. breve 2L genes involved in the transport and metabolism 
of hexose sugars.
The in vivo trials in a rat model clearly supported the notion that CG exploits a clear bifidogenic effect on 
bifidobacteria and in particular of small number of bifidobacterial species such as B. breve. These findings rein-
force the potential of GC in modulating and shaping the bifidobacterial communities especially in ecological 
Figure 5. Beta-diversity of CG, Breve2L and CG + Breve2L at T0, T1, T2 and T3 time points. Panels a,b,c and 
d report three dimensional PCoA obtained using Weighted Unifrac index for T0, T1, T2 and T3 time points, 
respectively.
Figure 6. Bacterial genera whose abundance is highly modulated by CG. The bar plot reports the average 
relative abundance observed in CG samples group of relevant genera modulated by CG supplementation.
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conditions where bifidobacteria are depleted (e.g., very often associated with metabolic disorders or gut diseases). 
In this context, the capability of bifidobacteria to use the CG as carbon source and the subsequent degradation of 
this bio-polymer in simpler derivatives, i.e. chitooligosaccharides (COS), may support the notion that CG act as 
a prebiotic. Indeed, it has been largely demonstrated that COS are able to inhibit the growth of pathogenic bacte-
ria24,25. Moreover, CG consumption was shown to reduce body weight increment in rats, thus pointing at CG as 
an interesting novel prebiotic for prevention and treatment of obesity.
Such in vivo data should be further confirmed by clinical trials performed in human beings consuming CG or 
CG-based products (e.g., symbiotic products) in those categories of individuals where bifidobacterial abundance 
is naturally low (e.g., in the elderly) or is depleted as a consequence of metabolic disorder (e.g., constipation) or 
diseases (auto-immune diseases) as well as antibiotic therapy.
It is also arguable that cross-feeding interactions might be established by the different members of the bifido-
bacterial communities as well as with the different members of the human gut microbiota for the complete metab-
olism of CG. This was previously shown in co-participated trophic interactions15,26 where a partner partially 
metabolizes GC in favor to another microorganism that is genetically incapable to utilize this substrate. Thus, 
cross-feeding might represent another valuable way exploited by CG to induce a more general prebiotic effect in 
the human gut.
Methods
Strains and culture conditions. Bifidobacterium strains used in this study are listed in Table 1. Strains 
were routinely grown anaerobically in De Man, Rogosa, Sharpe (MRS) medium (Scharlau) containing 2% glucose 
(w/v), which was supplemented with 0.05% L-cysteine-HCl and incubated at 37 °C for 24 h. Anaerobic conditions 
were achieved by the use of an anaerobic cabinet (Ruskin), in which the atmosphere consisted of 17% CO2, 80% 
N2, and 2.99% H2.
Ethical statement. All experimental procedures and protocols involving animals were approved by the 
Veterinarian Animal Care and Use Committee of Parma University (approved protocol 370/2018-PR) and con-
ducted in compliance with the European Community Council Directives dated 22 September 2010 (2010/63/UE).
Chitin-glucan growth assay. CG (KitoZyme, Belgium) was added to MRS without glucose (MRS w/o 
glu) at a final concentration of 0.5% (w/v), as previously assessed through growth experiments involving vari-
ous bifidobacteria on different carbon sources14. This growth medium was termed MRS w/o glu + CG and sub-
jected to sterilization employing a modified Tyndallization approach consisting of two thermal cycles at 80 °C for 
30 minutes each alternated with cooling in ice.
For all growth tests, cells were recovered from an overnight culture and turbidity was measured at 600 nm, 
using a biophotometer (Eppendorf). A growth tube containing 6 mL of MRS w/o glu + CG was inoculated with 
active viable bacterial cells diluted to an OD600nm of ~1.0, obtaining a final inoculum with an OD600nm of ~0.1. 
Cultures were grown in biologically independent triplicates and the resulting growth data sets were expressed 
as the means from these replicates. Moreover, positive (MRS) and negative (MRS w/o glu) growth controls were 
performed. Cultures were incubated under anaerobic conditions at 37 °C for 24 h. Cell growth was monitored 
using a Thoma cell counting chamber (Herka).
For some bifidobacterial strains, cell growth was also monitored by viable cell count in MRS Agar. For this 
purpose, strains were inoculated as mentioned above in MRS w/o glu + CG. Then, 1 mL of each grown strain was 
serially diluted in PBS (Phosphate buffered saline) and plated on MRS agar. Plates were incubated under anaero-
bic conditions at 37 °C for 48 h. Bacterial growth was assessed by colony counting.
RNA-Seq transcriptomic analysis and identification of genes induced by CG. Bacterial cells were 
recovered from an overnight culture and turbidity was measured at 600 nm, using a biophotometer (Eppendorf). 
A growth tube containing 40 mL of complete MRS (reference condition) as well as 40 ml of MRS w/o glu CG was 
inoculated with viable bacterial cells diluted to an OD600nm of ~1.0, obtaining a final inoculum with an OD600nm of 
~0.1. All growth conditions were performed by incubation in anaerobic cabinet at 37 °C. Following inoculation, 
Figure 7. B. breve 2L relative abundance respect to the total bifidobacterial population. The bar plot reports the 
average relative abundance of B. breve 2L observed in CG, Breve2L and CG + Breve2L at T0, T1, T2 and T3.
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growth was monitored and when an OD600nm value between 0.6 and 0.8 (exponential phase) cells were centrifuged 
at 6000 rpm for 5 min. Finally, prior to RNA extraction cells were frozen at −80 °C. Growth assays were carried 
out in triplicate. Total RNA was isolated from B. breve 2L cultures grown in MRS medium (Scharlau, Italy) as well 
as MRS w/o glu + GC. The obtained cell pellet was resuspended in 1 ml of QIAZOL (Qiagen, United Kingdom) 
and placed in a tube containing 0.8 g of glass beads (diameter, 106 μm; Sigma). Cells were lysed by shaking the 
mix on a Precellys 24 homogenizer (Bertin instruments, France). The mixture was then centrifuged at 13,000 rpm 
for 15 min, and the RNA-containing upper phase was recovered. RNA was further purified using RNeasy mini kit 
(Qiagen, UK) as reported in the manufacturer’s instructions.
RNA quality was checked by a Tape station 2200 (Agilent Technologies, USA) analysis. RNA concentration 
and purity were evaluated by Picodrop microliter spectrophotometer (Picodrop, UK).
For RNA sequencing, 2 μg of total RNA was treated to remove ribosomal RNA by the Ribo-Zero Magnetic Kit 
(Illumina), followed by purification of the rRNA-depleted sample by ethanol precipitation. RNA was processed 
according to the manufacturer’s protocol. The efficacy of rRNA depletion was checked by a Tape station 2200 
(Agilent Technologies). Then, 500 ng of rRNA-depleted RNAs was fragmented using Bioruptor NGS ultrason-
icator (Diagenode, USA) followed by size evaluation using Tape station 2200 (Agilent Technologies). A whole 
transcriptome library was constructed using the TruSeq Stranded RNA LT Kit (Illumina). Samples were loaded 
into a Flow cell V2 75 cycles (Illumina) as reported by the technical support guide.
Sequencing reads were mapped with Burrows-Wheeler Aligner (BWA)27 to the genomic sequence of B. breve 
2L (NCBI accession number AWUG00000000.1). Reads Per Kilobase per Million mapped reads (RPKM) of each 
gene were assessed using Artemis software28.
Animal housing. Experiments involved 5-month-old male wild-type Groningen rats (Rattus norvegi-
cus). After weaning, rats were housed in same sex sibling groups in rooms under humidity (50 ± 10%) and 
temperature-controlled conditions (22 ± 2 °C), a 12-h light-dark cycle (lights on at 7 a.m.), and with food and 
water available ad libitum.
Experimental design of the in vivo trials. From the initiation of the experiments, rats were housed indi-
vidually in polymethyl methacrylate (Plexiglas®) cages (39 cm × 23 cm × 15 cm). The first week represented an 
acclimatization period, during which rats continued to consume a standard chow diet supplemented with an oral 
administration of 500 µl of sucrose solution (2%) in order to adapt the rats to drink from the syringe. Maintaining 
their habits, rats could represent the negative control of themselves, acting as the baseline for subsequent micro-
biota analyses29. For the following two weeks (14 days), rats (n = 24) were randomized to 3 groups: a first group 
fed with standard diet supplemented with CG [90% standard diet (w/w) + 10% KiOnutrime-CG from KitoZyme, 
Belgium; CG group], a second group fed with a standard diet and an oral treatment with B. breve 2L (Breve2L 
group) and a third group fed with standard diet supplemented with CG (same composition of the CG group) 
and oral treatment with B. breve 2L (CG + Breve2L group) (Table 2). The CG group rats during the intervention 
period were orally inoculated with 500 µl of sucrose solution (2%) in order to maintain the same condition for 
the three groups except for the experimental variables. Finally, during the last week of the wash-out period, all 
animals returned to the standard chow diet.
Standard diet consisted of 54.61% nitrogen-free extract (mainly represented by starch and hemicellulose), 
5.54% fibers, 19.42% protein, 11.09% water, 2.58% lipids, and 6.76% ash (non-organic mineral matter) (3.9 kcal/g; 
4RF21, Mucedola, Italy). The percentage of supplementation of the substrate CG to standard chow diet was fixed 
at 10% (w/w) as previously illustrated6.
Food intake (FI) and body weight (BW) were measured daily and weekly, respectively, and the BW changes 
and FI were calculated as previously described7.
Evaluation of Bifidobacterium breve cell numbers by qPCR. Quantitative PCR (qPCR) was 
assessed using the species-specific primers BiBre1 (5′-CCGGATGCTCCATCACAC-3′) and BiBre2 
(5′-ACAAAGTGCCTTGCTCCCT-3′). qPCR was performed using GoTaq qPCR Master Mix (Promega, USA) 
on a CFX96 system (BioRad, CA, USA) following previously described protocols30. PCR products were detected 
with SYBR green fluorescent dye and amplified according to the following protocol: one cycle of 95 °C for 2 min, 
followed by 40 cycles of 95 °C for 3 s and 56 °C for 30 s. The melting curve was 65 °C to 95 °C with increments of 
0.5 °C/s. In each run, negative controls (no DNA) were included. A standard curve was built using the CFX96 
software (BioRad).
Fecal bacterial DNA extraction and 16S rRNA/ITS microbial profiling. Fecal samples were sub-
jected to DNA extraction using the QIAmp DNA Stool Mini Kit following the manufacturer’s instructions 
(Qiagen). Partial 16S rRNA gene sequences were amplified from extracted DNA using primer pair Probio_Uni/
Probio_Rev, which targets the V3 region of the 16S rRNA gene sequence31. Partial ITS sequences were ampli-
fied from extracted DNA using the primer pair Probio-bif_Uni/Probio-bif_Rev, which targets the spacer region 
between the 16S rRNA and the 23S rRNA genes within the ribosomal RNA (rRNA) locus22. Illumina adapter over-
hang nucleotide sequences were added to the partial 16S rRNA gene-specific amplicons and to the generated ITS 
amplicons of 200 bp, which were further processed using the 16S Metagenomic Sequencing Library Preparation 
Protocol (Part No. 15044223 Rev. B—Illumina). Amplifications were carried out using a Verity Thermocycler 
(Applied Biosystems). The integrity of the PCR amplicons was analyzed by electrophoresis on a 2200 TapeStation 
Instrument (Agilent Technologies, USA). DNA products obtained following PCR-mediated amplification of the 
16S rRNA gene sequences were purified by a magnetic purification step involving the Agencourt AMPure XP 
DNA purification beads (Beckman Coulter Genomics GmbH, Bernried, Germany) in order to remove primer 
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dimers. DNA concentration of the amplified sequence library was determined by a fluorimetric Qubit quantifi-
cation system (Life Technologies, USA). Amplicons were diluted to a concentration of 4 nM, and 5 µL quantities 
of each diluted DNA amplicon sample were mixed to prepare the pooled final library. 16S rRNA gene and ITS 
sequencing were performed using an Illumina MiSeq sequencer with MiSeq Reagent Kit v3 chemicals.
Metagenomics analyses. Following sequencing, the.fastq files were processed using a custom script based 
on the QIIME software suite32. Paired-end read pairs were assembled to reconstruct the complete Probio_Uni/ 
Probio_Rev and Probio-bif_Uni/Probio-bif_Rev amplicons. Quality control retained sequences with a length 
between 140 and 400 bp and mean sequence quality score >20 while sequences with homopolymers >7 bp and 
mismatched primers were omitted. In order to calculate downstream diversity measures (alpha and beta diver-
sity indices, Unifrac analysis), 16S rRNA Operational Taxonomic Units (OTUs) were defined at ≥99% sequence 
homology using uclust33 and OTUs with less than 10 sequences were filtered. ITS Operational Taxonomic Units 
(OTUs) were defined at 100% sequence homology using uclust33. All reads were classified to the lowest possible 
taxonomic rank using QIIME32 and a reference dataset from the SILVA database34 for 16S rRNA data or an 
updated version of the bifidobacterial ITS database22 for ITS data. Biodiversity of the samples (alpha-diversity) 
were calculated with Chao1 and Shannon indexes. Similarities between samples (beta-diversity) were calculated 
by unweighted uniFrac35. The range of similarities is calculated between the values 0 and 1. PCoA representations 
of beta-diversity were performed using QIIME32.
Statistical analysis. For in vitro trials, statistical significance between means was analyzed using the 
Student’s t-test. Values are expressed as the means ± standard errors from three experiments. Statistical calcula-
tions were performed using the software program GraphPad Prism 5 (La Jolla, CA, USA).
For in vivo experiments, two-way ANOVA for repeated measures with ‘group’ as between-subject factor (three 
levels: CG group, Breve2L group and CG + Bbreve2L group) was performed for: (i) BW changes, with ‘time’ as 
within-subject factor (three levels: T1, T2, T3); (ii) FI-to-BW ratio, with ‘time’ as within-subject factor (four lev-
els: week1, week2, week3 and week4). Follow up analysis was performed using Student’s t-test, with a Bonferroni 
correction for multiple comparisons.
Furthermore, the difference between the rarefaction curves and relative abundance of taxa, as well as the dif-
ferential abundance of bacterial genera were statistically analysed by t-test. All statistical analyses were performed 
through SPSS software (www.ibm.com/software/it/analytics/spss/).
Data Deposition. Raw sequences of 16S rRNA gene profiling and bifidobacterial ITS profiling as well as 
RNAseq data are accessible through SRA study accession numbers SRP164382 and SRP164394.
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